文献
J-GLOBAL ID:202202270641529275
整理番号:22A0764043
健康な日本人成人におけるCOVID-19ワクチンmRNA-1273の第1/2相無作為化プラセボ対照試験:中間報告
A phase 1/2 randomised placebo-controlled study of the COVID-19 vaccine mRNA-1273 in healthy Japanese adults: An interim report
著者 (6件):
Masuda Taisei
(Japan Development, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan)
,
Murakami Kyoko
(Japan Medical and Policy Affairs, Medical Affairs Office, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan)
,
Sugiura Kenkichi
(Statistical and Quantitative Sciences, Data Sciences Institute, Takeda Pharmaceutical Company Ltd, Japan)
,
Sakui Sho
(Statistical and Quantitative Sciences, Data Sciences Institute, Takeda Pharmaceutical Company Ltd, Japan)
,
Philip Schuring Ron
(Clinical Development, Global Vaccine Business Unit, Takeda Pharmaceutical International Ag, Switzerland)
,
Mori Mitsuhiro
(Japan Development, Global Vaccine Business Unit, Takeda Pharmaceutical Company Ltd, Japan)
資料名:
Vaccine (Web)
(Vaccine (Web))
巻:
40
号:
13
ページ:
2044-2052
発行年:
2022年
JST資料番号:
U1134A
ISSN:
0264-410X
資料種別:
逐次刊行物 (A)
記事区分:
原著論文
発行国:
アメリカ合衆国 (USA)
言語:
英語 (EN)